JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
JOHNSON & JOHNSON
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026
$253.79−1.77 (-0.69%)
Close on Oct 19, 2026
- Market cap
- $619.27B
- P/E (TTM)
- 29.4
- Dividend yield
- 2.03%
JOHNSON & JOHNSON revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $60.40B | $56.96B | $54.76B | $52.56B | $51.68B | – | – | – | – | – | 64.1% | +6.0% |
| MEDTECH | $33.79B | $31.86B | $30.40B | $27.43B | $27.06B | $22.96B | – | – | – | – | 35.9% | +6.1% |
| Consumer Health | – | – | – | $14.95B | $15.04B | $14.45B | $13.90B | $13.85B | $13.60B | $13.31B | – | – |
| Pharmaceutical | – | – | – | $52.56B | $51.68B | $45.18B | $42.20B | $40.73B | $36.26B | $33.46B | – | – |
| MedTech | – | – | – | – | $27.06B | $22.96B | $25.96B | $26.99B | $26.59B | $25.12B | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. [Member] | $53.75B | $50.30B | $46.44B | $41.98B | $40.64B | $43.13B | $42.10B | $41.88B | $39.86B | $37.81B | 57.1% | +6.9% |
| International | $40.44B | $38.52B | $38.72B | $38.01B | $38.10B | $39.45B | $39.96B | $39.70B | $36.59B | $34.08B | 42.9% | +5.0% |
| Europe | $21.54B | $20.21B | $20.41B | $20.66B | $20.60B | $18.98B | $18.47B | $18.75B | $17.13B | $15.77B | 22.9% | +6.5% |
| Asia-Pacific, Africa | $14.03B | $13.59B | $13.76B | $13.24B | $13.58B | $15.14B | $15.56B | $14.83B | $13.42B | $12.58B | 14.9% | +3.2% |
| Western Hemisphere, excluding U.S. | $4.88B | $4.71B | $4.55B | $4.11B | $3.93B | $5.34B | $5.94B | $6.11B | $6.04B | $5.73B | 5.2% | +3.4% |
| Operating Segments | – | – | – | – | – | – | – | – | $76.45B | $71.89B | – | – |
From the segment and revenue-disaggregation notes of Johnson & Johnson's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.